Lymphedema Panel
Use
The Lymphedema Panel is designed for individuals who exhibit features or have a clinical or suspected diagnosis of hereditary lymphedema. It is particularly relevant for individuals experiencing asymmetric or bilateral lymphedema not caused by cancer or previous lymphadenectomy, and for those with lymphedema onset before age 20.
Special Instructions
The test is conducted on either the Exome or Genome platform, using Next-Generation Sequencing (NGS) with CNV analysis. Exome platform accepts various specimen types including blood, DNA, buccal, saliva, and tissue, while the Genome platform accepts blood and DNA. STAT testing is available for expedited processing, which is subject to a surcharge unless delivery is delayed beyond 16 days with a blood sample.
Limitations
This test may not detect all genetic variants associated with lymphedema, particularly deep intronic mutations or regulatory region variants not covered by the used NGS platform. Detection of copy number variants (CNVs) is limited to those with adequate evidence of clinical relevance. Results may be influenced by improper sample collection or handling, contamination, or degradation during storage or shipping.
New York Approved
Methodology
NGS
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided